S&P 500   4,109.31 (+1.44%)
DOW   33,274.15 (+1.26%)
QQQ   320.93 (+1.66%)
AAPL   164.90 (+1.56%)
MSFT   288.30 (+1.50%)
META   211.94 (+1.97%)
GOOGL   103.73 (+2.81%)
AMZN   103.29 (+1.26%)
TSLA   207.46 (+6.24%)
NVDA   277.77 (+1.44%)
NIO   10.51 (+0.48%)
BABA   102.18 (-1.16%)
AMD   98.01 (+0.13%)
T   19.25 (+0.89%)
F   12.60 (+2.52%)
MU   60.34 (-4.36%)
CGC   1.75 (-0.57%)
GE   95.60 (+1.65%)
DIS   100.13 (+2.07%)
AMC   5.01 (+0.80%)
PFE   40.80 (+1.04%)
PYPL   75.94 (+2.08%)
NFLX   345.48 (+2.08%)
S&P 500   4,109.31 (+1.44%)
DOW   33,274.15 (+1.26%)
QQQ   320.93 (+1.66%)
AAPL   164.90 (+1.56%)
MSFT   288.30 (+1.50%)
META   211.94 (+1.97%)
GOOGL   103.73 (+2.81%)
AMZN   103.29 (+1.26%)
TSLA   207.46 (+6.24%)
NVDA   277.77 (+1.44%)
NIO   10.51 (+0.48%)
BABA   102.18 (-1.16%)
AMD   98.01 (+0.13%)
T   19.25 (+0.89%)
F   12.60 (+2.52%)
MU   60.34 (-4.36%)
CGC   1.75 (-0.57%)
GE   95.60 (+1.65%)
DIS   100.13 (+2.07%)
AMC   5.01 (+0.80%)
PFE   40.80 (+1.04%)
PYPL   75.94 (+2.08%)
NFLX   345.48 (+2.08%)
S&P 500   4,109.31 (+1.44%)
DOW   33,274.15 (+1.26%)
QQQ   320.93 (+1.66%)
AAPL   164.90 (+1.56%)
MSFT   288.30 (+1.50%)
META   211.94 (+1.97%)
GOOGL   103.73 (+2.81%)
AMZN   103.29 (+1.26%)
TSLA   207.46 (+6.24%)
NVDA   277.77 (+1.44%)
NIO   10.51 (+0.48%)
BABA   102.18 (-1.16%)
AMD   98.01 (+0.13%)
T   19.25 (+0.89%)
F   12.60 (+2.52%)
MU   60.34 (-4.36%)
CGC   1.75 (-0.57%)
GE   95.60 (+1.65%)
DIS   100.13 (+2.07%)
AMC   5.01 (+0.80%)
PFE   40.80 (+1.04%)
PYPL   75.94 (+2.08%)
NFLX   345.48 (+2.08%)
S&P 500   4,109.31 (+1.44%)
DOW   33,274.15 (+1.26%)
QQQ   320.93 (+1.66%)
AAPL   164.90 (+1.56%)
MSFT   288.30 (+1.50%)
META   211.94 (+1.97%)
GOOGL   103.73 (+2.81%)
AMZN   103.29 (+1.26%)
TSLA   207.46 (+6.24%)
NVDA   277.77 (+1.44%)
NIO   10.51 (+0.48%)
BABA   102.18 (-1.16%)
AMD   98.01 (+0.13%)
T   19.25 (+0.89%)
F   12.60 (+2.52%)
MU   60.34 (-4.36%)
CGC   1.75 (-0.57%)
GE   95.60 (+1.65%)
DIS   100.13 (+2.07%)
AMC   5.01 (+0.80%)
PFE   40.80 (+1.04%)
PYPL   75.94 (+2.08%)
NFLX   345.48 (+2.08%)

Tonix Pharmaceuticals - TNXP Competitors

$0.59
-0.02 (-3.27%)
(As of 03/31/2023 12:00 AM ET)
Add
Compare
Today's Range
$0.58
$0.64
50-Day Range
$0.56
$1.23
52-Week Range
$0.29
$7.71
Volume
795,119 shs
Average Volume
3.57 million shs
Market Capitalization
$37.04 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$12.85

TNXP vs. APLT, LPTX, ASLN, SLS, HOOK, DMAC, CRVS, CRBP, ACXP, and YMTX

Should you be buying Tonix Pharmaceuticals stock or one of its competitors? The main competitors of Tonix Pharmaceuticals include Applied Therapeutics (APLT), Leap Therapeutics (LPTX), ASLAN Pharmaceuticals (ASLN), SELLAS Life Sciences Group (SLS), Hookipa Pharma (HOOK), DiaMedica Therapeutics (DMAC), Corvus Pharmaceuticals (CRVS), Corbus Pharmaceuticals (CRBP), Acurx Pharmaceuticals (ACXP), and Yumanity Therapeutics (YMTX). These companies are all part of the "pharmaceutical preparations" industry.

Tonix Pharmaceuticals vs.

Tonix Pharmaceuticals (NASDAQ:TNXP) and Applied Therapeutics (NASDAQ:APLT) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, risk, valuation, community ranking, media sentiment, analyst recommendations, profitability, institutional ownership and earnings.

Tonix Pharmaceuticals received 273 more outperform votes than Applied Therapeutics when rated by MarketBeat users. Likewise, 67.67% of users gave Tonix Pharmaceuticals an outperform vote while only 54.70% of users gave Applied Therapeutics an outperform vote.

CompanyUnderperformOutperform
Tonix PharmaceuticalsOutperform Votes
337
67.67%
Underperform Votes
161
32.33%
Applied TherapeuticsOutperform Votes
64
54.70%
Underperform Votes
53
45.30%

Applied Therapeutics is trading at a lower price-to-earnings ratio than Tonix Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Tonix PharmaceuticalsN/AN/A-$110.22 million-$4.07-0.15
Applied TherapeuticsN/AN/A-$82.51 million-$2.40-0.34

Tonix Pharmaceuticals currently has a consensus price target of $12.85, suggesting a potential upside of 2,073.91%. Applied Therapeutics has a consensus price target of $10.42, suggesting a potential upside of 1,184.26%. Given Tonix Pharmaceuticals' stronger consensus rating and higher probable upside, equities analysts plainly believe Tonix Pharmaceuticals is more favorable than Applied Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Tonix Pharmaceuticals
0 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
3.00
Applied Therapeutics
0 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.50

In the previous week, Applied Therapeutics had 4 more articles in the media than Tonix Pharmaceuticals. MarketBeat recorded 4 mentions for Applied Therapeutics and 0 mentions for Tonix Pharmaceuticals. Tonix Pharmaceuticals' average media sentiment score of 1.87 beat Applied Therapeutics' score of 0.94 indicating that Tonix Pharmaceuticals is being referred to more favorably in the media.

Company Overall Sentiment
Tonix Pharmaceuticals Very Positive
Applied Therapeutics Positive

Tonix Pharmaceuticals has a beta of 2.18, suggesting that its share price is 118% more volatile than the S&P 500. Comparatively, Applied Therapeutics has a beta of 1.9, suggesting that its share price is 90% more volatile than the S&P 500.

Tonix Pharmaceuticals' return on equity of -50.54% beat Applied Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Tonix Pharmaceuticals N/A -50.54% -45.53%
Applied Therapeutics N/A -383.75% -131.25%

9.7% of Tonix Pharmaceuticals shares are owned by institutional investors. Comparatively, 62.9% of Applied Therapeutics shares are owned by institutional investors. 0.8% of Tonix Pharmaceuticals shares are owned by insiders. Comparatively, 17.0% of Applied Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

Tonix Pharmaceuticals beats Applied Therapeutics on 10 of the 15 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TNXP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

TNXP vs. The Competition

MetricTonix PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$37.04M$5.66B$4.41B$6.04B
Dividend YieldN/A2.59%2.43%6.33%
P/E Ratio-0.155.4497.7213.25
Price / SalesN/A284.553,571.9856.29
Price / CashN/A17.9228.3065.84
Price / Book0.164.304.605.10
Net Income-$110.22M$187.05M$114.74M$191.80M
7 Day Performance2.41%3.11%2.45%2.75%
1 Month Performance-15.56%-6.20%-5.23%-4.07%
1 Year Performance-91.98%-9.58%-13.99%-15.84%

Tonix Pharmaceuticals Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
APLT
Applied Therapeutics
2.5654 of 5 stars
$0.80
-3.6%
$4.13
+412.8%
-64.7%$38.70MN/A-0.3434Short Interest ↓
News Coverage
Positive News
LPTX
Leap Therapeutics
1.8468 of 5 stars
$0.33
flat
$2.80
+754.7%
-81.2%$38.90M$1.50M-0.6836Earnings Report
Short Interest ↑
Analyst Revision
News Coverage
Gap Up
ASLN
ASLAN Pharmaceuticals
2.072 of 5 stars
$2.79
+5.7%
$18.75
+572.0%
-38.3%$38.92MN/A-0.7518Analyst Revision
SLS
SELLAS Life Sciences Group
2.1029 of 5 stars
$1.38
+10.4%
$7.00
+407.2%
-79.9%$39.06M$1M-0.627Positive News
Gap Up
HOOK
Hookipa Pharma
1.9935 of 5 stars
$0.72
-1.4%
$5.50
+663.6%
-64.9%$39.42M$14.25M-0.6956Positive News
Gap Up
DMAC
DiaMedica Therapeutics
1.8623 of 5 stars
$1.50
+2.0%
$10.00
+566.7%
-40.9%$39.69MN/A-3.1314Earnings Report
Short Interest ↑
News Coverage
CRVS
Corvus Pharmaceuticals
2.1201 of 5 stars
$0.79
+9.7%
$3.00
+277.9%
-49.4%$36.96MN/A-0.9028Analyst Report
Short Interest ↑
News Coverage
CRBP
Corbus Pharmaceuticals
1.6987 of 5 stars
$8.83
+9.7%
$3.00
-66.0%
+1,624.6%$36.82M$880,000.00-0.8541Positive News
ACXP
Acurx Pharmaceuticals
1.899 of 5 stars
$3.35
-3.7%
$14.00
+317.9%
-3.2%$40.49MN/A-2.993Short Interest ↑
YMTX
Yumanity Therapeutics
0 of 5 stars
$3.35
+5.3%
N/A+93.9%$36.37M$4.84M-1.1240
This page (NASDAQ:TNXP) was last updated on 3/31/2023 by MarketBeat.com Staff